Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Disease Analysis: Acute Myeloid Leukemia (AML)
Read More
AML is a type of heterogeneous hematological malignancy that originates from immature white blood cells (blasts) in the bone marrow, which may be derived from either a hematopoietic stem cell or a lineage-specific progenitor cell. “Acute” means that the leukemia may progress rapidly – AML generally spreads quickly to the bloodstream and can then spread to other parts of the body including the lymph nodes, spleen, central nervous system, and testicles.
April 11, 2022
Find out more
Key Trends in European Market Access

$2,995.00

This strategy report focuses on Key Trends in European Market Access including accelerating access to medicines, health technology assessment and harmonization, developments in health technology assessment, pricing, and reimbursement delays.
January 26, 2016
Find out more
2015 Breast Cancer Pulse #3

$599.00

We performed a 5-question survey of 25 oncologists in the US to gauge current prescribing practices for breast cancer treatments.
June 12, 2015
Find out more
Renal Cell Carcinoma KOL Interview – US, Southeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for renal cell carcinoma. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Cabometyx, Keytruda, Inlyta, Lenvima, and Tecentriq.
May 13, 2020
Find out more
Viibryd
Read More
Viibryd (vilazodone; Allergan) belongs to a new class of antidepressants, combining selective serotonin reuptake inhibitor activity with partial 5-HT1A receptor agonism, in order to produce its therapeutic effect.
March 29, 2019
Find out more
esuberaprost
Read More
Esuberaprost (United Therapeutics) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, and also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.
October 29, 2018
Find out more
Disease Analysis: COVID-19 Treatment
Read More
COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of 12 March 2021, there have been 117,799,584 confirmed cases of COVID-19, and 2,615,018 confirmed deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus. SARS-CoV-2 is believed to have originated from a horseshoe bat coronavirus, which either spread to humans directly or jumped via an intermediate host (possibly a pangolin), which may have facilitated transmission to humans.
November 1, 2021
Find out more
Betrixaban
Read More
Betrixaban (Portola Pharmaceuticals) is an oral, once-daily inhibitor of factor Xa that catalyzes conversion of prothrombin to thrombin, preventing thrombosis. Betrixaban is currently in Phase III development…
August 2, 2016
Find out more
Ninlaro
Read More
Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways.
August 9, 2018
Find out more
Tobi/Tobi Podhaler
Read More
Tobi and the next-generation Tobi Podhaler are the gold-standard inhaled antibiotic treatments for cystic fibrosis patients.
September 3, 2018
Find out more
Mavyret
Read More
Mavyret ([glecaprevir + pibrentasvir]) is AbbVie’s next-generation, pan-genotypic regimen, which is positioned as a replacement for the Viekira Pak franchise ([paritaprevir + ritonavir + ombitasvir] ± dasabuvir) and is intended to reverse the company’s hepatitis C revenue decline. Mavyret is forecasted to achieve greater commercial success than its predecessor, and will allow AbbVie to quickly recoup the genotype 1/4 (GT-1/4) patient share lost to Zepatier ([grazoprevir + elbasvir]; Merck & Co) during 2016–17 because of its more attractive eight-week dosing schedule in non-cirrhotic patients, as well as AbbVie’s anticipated willingness to discount heavily to achieve uptake.
November 6, 2017
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *